Physician profile
Jon M Shrader
NPI 1447245980
$494.91
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $146.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $112.74 | 2019 | |
| Mylan Specialty L.P. | $101.84 | 2019-2020 | |
| Pfizer INC. | $41.84 | 2019 | |
| Shire North American Group INC | $37.03 | 2019 | |
| Biogen, INC. | $34.60 | 2020 | |
| Daiichi Sankyo INC. | $21.15 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.76 | 2020 | |
| Amgen INC. | $16.83 | 2019 | |
| Amarin Pharma, INC. | $16.37 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2019 | |
| Allergan, INC. | $14.49 | 2019 | |
| Hologic Sales and Service, LLC | $13.42 | 2020 | |
| Pacira Therapeutics, INC. | $13.24 | 2019 | |
| Novo Nordisk INC | $12.66 | 2020 | |
| Boston Scientific Corporation | $12.60 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $11.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Shrader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.